Bradley Foster & Sargent Inc. CT Buys New Holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Bradley Foster & Sargent Inc. CT purchased a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 56,663 shares of the company’s stock, valued at approximately $871,000. Bradley Foster & Sargent Inc. CT owned about 0.21% of ClearPoint Neuro at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of CLPT. R Squared Ltd bought a new position in shares of ClearPoint Neuro in the fourth quarter worth approximately $32,000. Barclays PLC boosted its position in ClearPoint Neuro by 24.3% during the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock valued at $64,000 after buying an additional 1,109 shares during the period. JPMorgan Chase & Co. grew its holdings in ClearPoint Neuro by 58.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock worth $110,000 after acquiring an additional 3,612 shares during the last quarter. Verition Fund Management LLC purchased a new position in shares of ClearPoint Neuro in the third quarter valued at about $123,000. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of ClearPoint Neuro in the third quarter valued at about $156,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Trading Down 4.2 %

NASDAQ:CLPT opened at $16.72 on Friday. The company has a 50-day moving average price of $16.61 and a 200-day moving average price of $13.62. The stock has a market cap of $461.14 million, a price-to-earnings ratio of -24.23 and a beta of 1.03. ClearPoint Neuro, Inc. has a 12 month low of $5.11 and a 12 month high of $19.22.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CLPT. B. Riley raised their target price on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Lake Street Capital lifted their price objective on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, January 21st.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.